Thanks for pointing that out. I was trying to be slightly facetious in my post by quoting CB Pharma's November 25, 2015 press release that included the November 18, 2015 letter to National Holdings' Chairman. It stated, "The offer price in cash represents a 32% premium over the Company's closing price on November 17, 2015. The offer price in stock of CB represents a 42% premium over the Company's closing price on November 17, 2015."
It is such a silly statement on the face of it. NHLD is a low volume stock, and the difference between the bid and the ask can consume most of CB's "premium". At one point during the week prior to the offer, NHLD had a bid-ask spread of more than 20%. That is the reason I put quotes around the word "premium".
<<Weiss and Rosenwald are not strangers to NHLD, and CB’s 32%-42% "premium" offer price is severely lacking.>>
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM